# Amide Proton Transfer (APT) MRI of Brain Tumors at 3T

> **NIH NIH R01** · JOHNS HOPKINS UNIVERSITY · 2021 · $388,521

## Abstract

ABSTRACT
 Gliomas, the most common primary brain tumors, are biologically complex and exhibit substantial
molecular and phenotypic spatial variation. A major obstacle in both the daily management of patients with
gliomas, and in the development of new therapies for these cancers, is the inability of neuroimaging to
accurately define the tumor burden. Specifically, gadolinium (Gd) enhancement reveals focal areas of
malignant gliomas where the blood-brain barrier (BBB) is disrupted, but it does not show large high-risk areas
of infiltrating tumor with a high cellularity. The recent breakthrough in the understanding of genetic features in
gliomas, such as isocitrate dehydrogenase (IDH) mutations, has resulted in a prompt reappraisal of the
molecular oncogenesis of this group of diseases. Notably, the most recent 2016 WHO classification of CNS
tumors uses molecular parameters, in addition to histology, to define tumor entities. The 2016 CNS WHO
represents an unmet radiographic need, namely, the identification of genetic biomarkers preoperatively, with
non-invasive methods such as MRI. This project has been very successful during the 2nd funding period (9/13-
7/17) in developing an important protein-based molecular MRI technology, called amide proton transfer-
weighted (APTw) imaging, into a sensitive, user-friendly, and reproducible approach for routine clinical use.
Numerous early clinical data have demonstrated that APTw imaging adds important value to the standard
clinical MRI sequences in brain cancer diagnosis. Compared to the contralateral normal-appearing brain
tissue, the conspicuous, highly reproducible APTw hyperintensity can always be visualized in high-grade
gliomas (including those without Gd enhancement). Thus, APTw imaging allowed accurate identification of
high-grade regions within heterogeneous gliomas—a core need during neurosurgical procedures. Notably, we
have recently found that the APTw signal could be a valuable imaging biomarker by which to identify IDH
mutation status in low-grade gliomas. These early findings are very exciting. However, all currently used
imaging protocols are essentially not quantitative, and the images obtained are often called APT-weighted
images because of other contributions. The overall goals of this renewal application are to develop highly
sensitive, fast, and quantitative APT-MRI methodologies on 3T clinical MRI scanners and to evaluate the
potential of these methodologies in brain cancer molecular diagnosis. We have designed the following specific
aims: (i) develop quantitative APT-MRI methodologies using compressed sensing at 3T; (ii) determine the
capability of APT-MRI for the prediction of IDH mutation status in grade-II gliomas; and (iii) determine the
accuracy of APT-MRI for the identification of high-risk regions of tumor outside Gd-enhancing masses in
patients with glioblastomas. If successful, our results will significantly push, to a whole new level, the APT-MRI
methodology research and cl...

## Key facts

- **NIH application ID:** 10063492
- **Project number:** 5R01CA228188-11
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** JINYUAN ZHOU
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $388,521
- **Award type:** 5
- **Project period:** 2018-12-01 → 2022-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10063492

## Citation

> US National Institutes of Health, RePORTER application 10063492, Amide Proton Transfer (APT) MRI of Brain Tumors at 3T (5R01CA228188-11). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10063492. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*